Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

A shorter course of prophylactic antibiotics, or even no course at all, appeared to be noninferior to longer courses in ...

In hospitalized patients with acute kidney injury and liver cirrhosis, baseline and peak levels of serum cystatin C can ...

Gastroenterologist Dr Salhab warns that liver cirrhosis can lead to overt hepatic encephalopathy, impacting brain function and overall well-being.

FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

About Rezdiffra Rezdiffra is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. It is the first approved medication for the treatment of MASH in the US ...

When the liver is badly scarred by cirrhosis, the consequences are not just digestive. It can creep up and affect your brain ...

The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...

Indian scientists developed treatment for liver cirrhosis, accompanied by the distortion of both blood and lymphatic vessels in the liver and the intestine ...